

Ipsogen announces the success of a € 1.9 million reserved capital increase

Marseille, 17 June 2010 - **IPSOGEN** (the « Company » ; Alternext - FR0010626028 – ALIPS), a cancer « profiler » company that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today announces that it has successfully completed a €1.9 million capital increase reserved for qualified investors.

Through this capital increase, which was managed by Portzamparc, a total of 211 200 shares were issued at a price of €9.20 each.

Pursuant to the delegation of the Company's Annual General Meeting held on May 20, 2009, this fundraising has been implemented in the context of the French « TEPA » law (which allows a reduction of the French Wealth Tax in favor of investments in SMEs). It will strengthen the Company's already robust balance sheet in order to support its ambitious development plan.

Vincent FERT, CEO of IPSOGEN, states: « This capital increase has been successfully subscribed by some of our historical shareholders and by new investors. With a price of €9.20 per share, it reinforces our financial structure with a very limited dilution effect. This success confirms the confidence of the market in Ipsogen' long term growth potential in the fast growing market of cancer molecular diagnostics and personalized medicine ».

About IPSOGEN

Ipsogen, Cancer Profiler, develops and markets molecular diagnostic tests designed to map diseases in order to guide patients and oncologists decisions along their complex therapeutic path.

With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that remained unavailable until now.

Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly-skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society.

Ipsogen employed 65 people as of December 31, 2009. Its headquarters are located in Marseille, France.

The company has also a subsidiary, Ipsogen Inc., in Stamford, CT, USA.

For more information, visit us at: www.ipsogen.com

Contacts



IPSOGEN

Vincent Fert

CEO

Tel.: + 33 (0)4 9129 3090

fert@ipsogen.com

Pascale Boissel

CFO

Tel.: + 33 (0)4 9129 3090

pascale.boissel@ipsogen.com

NewCap.

Financial Communication and Investor Relations

Axelle Vuillermet & Pierre Laurent

Tel.: + 33 (0)1 44 71 94 93

ipsogen@newcap.fr